Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00733278 · ClinicalTrials.gov registry record · Phase 4

Intrauterine Contraceptive Device (IUD) Placement at Time of C-Section

A Phase 4 study of Contraception, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

Completed
Registry status
Phase 4
Development phase
7
Enrollment target
1
Study location

NCT00733278 is a Phase 4 study of Contraception that has completed, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 7 participants, below the 455-participant average among 72 other Contraception trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00733278, a Phase 4 study of Contraception, has completed, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

This is a pilot study of up to 10 women, which will test the hypothesis that the placement of copper IUDs through the uterine incision at the time of uncomplicated elective C-section is technically feasible and acceptable to women seeking long-term contraception.

Conditions Studied

Interventions

  • DEVICE Copper IUD ( ParaGard Intrauterine Contraceptive Device)

Study Locations (1)

California

  • Los Angeles BRI - Torrance

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2007-11
Est. Completion 2008-09
Phase Phase 4

What the Registry Record Tells You About NCT00733278

The ClinicalTrials.gov registry entry for NCT00733278 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 455-participant average among 72 other Contraception trials with a reported enrollment target (98% lower). The listed sponsor is Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which Copper IUD ( ParaGard Intrauterine Contraceptive Device) is the first listed.

NCT00733278 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00733278 about?

NCT00733278 is a clinical study titled "Intrauterine Contraceptive Device (IUD) Placement at Time of C-Section". This is a pilot study of up to 10 women, which will test the hypothesis that the placement of copper IUDs through the uterine incision at the time of uncomplicated elective C-section is technically feasible and acceptable to women seeking long-term contraception.

What is the current status of trial NCT00733278?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2007-11. Estimated completion is 2008-09.

What conditions does trial NCT00733278 study?

This clinical trial studies the following conditions: Contraception.

What interventions are being tested in trial NCT00733278?

The interventions under investigation include: Copper IUD ( ParaGard Intrauterine Contraceptive Device) (DEVICE).

Who is sponsoring clinical trial NCT00733278?

This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00733278 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Contraception

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.